Aardvark Therapeutics, Inc. (NASDAQ:AARD – Get Free Report) has been given an average rating of “Hold” by the twelve research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $15.33.
AARD has been the topic of several recent research reports. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $6.00 price target on shares of Aardvark Therapeutics in a research report on Thursday, September 24th. Weiss Ratings raised Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. HC Wainwright reissued a “neutral” rating and issued a $6.00 price objective on shares of Aardvark Therapeutics in a research note on Monday, July 20th. Finally, Wall Street Zen upgraded Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th.
Get Our Latest Stock Analysis on AARD
Key Stories Impacting Aardvark Therapeutics
- Neutral Sentiment: Several law firms are soliciting investors to serve as lead plaintiffs in a pending securities class action, with an October 13, 2026 deadline. The notices target investors who bought Aardvark shares in or traceable to the February 2025 IPO or during the February 13, 2025–May 14, 2026 class period. AARD 2-Week Deadline Alert
- Negative Sentiment: Pomerantz and other firms say a class action has been filed against Aardvark and certain officers and directors. The lawsuits allege that company disclosures and IPO materials overstated ARD-101’s safety and described it as approximately “99% gut-restricted” while failing to adequately disclose systemic-exposure risks. The allegations point to the subsequent Phase 3 safety pause and full FDA clinical hold on ARD-101, events that reportedly caused the stock to lose more than 70% of its IPO value. The claims have not been proven, but the litigation may increase legal costs, reputational risk and uncertainty surrounding ARD-101’s development. Pomerantz Class Action Announcement
Aardvark Therapeutics Trading Up 1.5%
Aardvark Therapeutics stock opened at $5.35 on Wednesday. Aardvark Therapeutics has a 1-year low of $3.35 and a 1-year high of $17.94. The firm has a market capitalization of $117.06 million, a price-to-earnings ratio of -1.67 and a beta of 3.74. The firm’s fifty day moving average price is $6.14 and its two-hundred day moving average price is $5.27.
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.21. On average, research analysts forecast that Aardvark Therapeutics will post -3.17 EPS for the current year.
Insider Transactions at Aardvark Therapeutics
In related news, insider Nelson Sun sold 62,000 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $5.18, for a total value of $321,160.00. Following the completion of the sale, the insider directly owned 35,475 shares of the company’s stock, valued at approximately $183,760.50. This represents a 63.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 17.80% of the company’s stock.
Hedge Funds Weigh In On Aardvark Therapeutics
A number of hedge funds have recently bought and sold shares of AARD. Susquehanna International Group LLP purchased a new stake in shares of Aardvark Therapeutics in the second quarter valued at about $138,000. Bank of New York Mellon Corp boosted its holdings in Aardvark Therapeutics by 30.8% during the first quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock worth $111,000 after purchasing an additional 6,905 shares during the last quarter. Ieq Capital LLC purchased a new position in Aardvark Therapeutics during the second quarter worth about $221,000. J. Goldman & Co LP purchased a new position in Aardvark Therapeutics during the second quarter worth about $233,000. Finally, Propel Bio Management LLC bought a new stake in Aardvark Therapeutics in the 4th quarter worth about $609,000.
About Aardvark Therapeutics
Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for obesity, hyperphagia and related metabolic disorders. The company’s approach is based on activating bitter taste receptors, which it believes may influence appetite regulation and metabolic signaling without relying on injectable therapies.
Aardvark’s lead investigational product, ARD-101, is an oral small-molecule bitter taste receptor agonist being studied for conditions involving excessive hunger and food intake, including hyperphagia associated with Prader-Willi syndrome.
Featured Stories
- Five stocks we like better than Aardvark Therapeutics
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
